Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Exclusive: Ernst, audit clients cut lobbying ties-records

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:11am CEST

Ernst & Young's lobbying unit is no longer listed as a lobbyist for three major U.S. companies, all of whom were 2011 audit clients of the accounting giant. The deregistration follows questions raised by two U.S. senators in March about whether the dual relationships crossed auditor independence boundaries.

Documents filed last month with Congress showed that Washington Council Ernst & Young, the E&Y unit, was no longer registered as doing lobbying work for Amgen Inc (>> Amgen, Inc.), CVS Caremark Corp (>> CVS Caremark Corporation) and Verizon Communications Inc (>> Verizon Communications Inc.).

A lobbying-contract termination was also filed on March 31 for a fourth company, Nomura Holdings Inc (>> Nomura Holdings Inc.), which, according to securities filings, uses an E&Y affiliate for auditing services. E&Y had provided lobbying services to Nomura since June 2011, according papers on file with Congress.

Auditors that review corporations' books every year must follow rules limiting other ties with audit clients. The rules - meant to prevent auditors from getting too cozy with audit clients - were substantially beefed up a decade ago after a rash of accounting scandals at Enron Corp. and other companies.

An Ernst & Young spokesman declined to comment on the discontinued lobbying relationships. Officials with Nomura, Verizon and CVS declined to comment. Amgen officials could not immediately be reached for comment.

The chief accountant for the U.S. Securities and Exchange Commission, James Kroeker, speaking at a financial reporting conference at Baruch College in New York on Thursday, said SEC rules state an auditor should not act in an advocacy role for a company it audits and lobbying would be inconsistent with that.

Kroeker did not mention any audit firms by name.

He said: "If you think about lobbying in the traditional sense, you would say, 'wouldn't somebody that's lobbying be placing themselves in a position to be an advocate?'"

Asked whether the SEC was looking into E&Y's lobbying activities, an official in the agency's enforcement division declined to comment because its investigations are not public.

"We are aware of it and we are cognizant of what the rules are," said Howard Scheck, chief accountant of the SEC's division of enforcement, on the sidelines of Thursday's conference.

"If there's a violation that we find, we'll certainly do something about that," he said, without referring to E&Y.

Reuters reported in March that Washington Council Ernst & Young had been hired as a lobbyist for a number of E&Y's audit clients, prompting two lawmakers to demand closer scrutiny.

Democratic senators Carl Levin and Jack Reed both expressed concerns at the time and urged the SEC to look into the matter. On Thursday, Reed's office did not immediately respond to inquiries seeking comment. Levin's office declined to comment.

Verizon had a particularly long relationship with E&Y's lobbyists, who helped the telecommunications company with tax issues beginning in September 2001. The two other lobbying relationships were more recent, dating to February in the case of Amgen and September in the case of CVS Caremark. Both contracts were connected to corporate tax debates. The three U.S. terminations were all effective March 31 and Nomura's termination was filed the same day.

The E&Y spokesman referred Reuters to its earlier statement that Washington Council's work complied with independence rules.

The work was approved by clients' audit committees and it was limited to tax-related issues, E&Y spokesman Charles Perkins said when Reuters reported on the issue in March.

Washington Council did not solicit votes on legislation for E&Y audit clients, Perkins said.

The Public Company Accounting Oversight Board, the watchdog for U.S. auditors, is looking to shore up independence rules after finding numerous instances in which auditors did not dig deeply enough to challenge clients' financial numbers.

The SEC's Kroeker said he was encouraged to see the board tackling the subject.

"Independence is really the bedrock, the foundation of the value that's provided by a third-party audit," he said.

(Reporting by Dena Aubin and David Ingram; Additional reporting by Kim Dixon; Editing by Kevin Drawbaugh and Matt Driskill)

By David Ingram and Dena Aubin

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
05/25 CVS HEALTH : Standoff with armed robber at Media CVS ends peacefully
05/24 CVS HEALTH : Petition urges Laguna Beach planners to deny CVS' application
05/23 CVS HEALTH : Attorney General Brnovich, Rep. Carter Join CVS Health to Announce ..
05/19 CVS HEALTH CORP (NYSE : CVS) Omnicare Unit Agrees To Pay Up To $8 Million For Fa..
05/19 CVS HEALTH : Removing Chemicals of Consumer Concern
05/18 CVS HEALTH : American Lung Association's LUNG FORCE Encourages Americans to Take..
05/17 Wells Fargo, CVS tumble; Target and Red Robin Gourmet gain
05/17DJCVS HEALTH : Why Your Pharmacy May Be Texting You -- WSJ
05/16 CVS HEALTH CORP (NYSE : CVS) Unveils Long Live Skin Campaign As Part Of Skin Can..
05/16 CVS HEALTH : Kicking the habit
More news
Sector news : Drug Retailers - NEC
05/15 SHANGHAI PHARMACEUTICALS : Advent, Shanghai Pharma have not approached Stada - s..
05/02 CVS HEALTH : profit beats as pharmacy margins rise
04/26 PayPal's profit, revenue beat on higher processing volumes
04/26DJANTHEM : Says ACA Payment Loss Could Cause 20% Premium Hike -- Update
04/26DJExpress Scripts Faces Tough Test -- WSJ
More sector news : Drug Retailers - NEC
News from SeekingAlpha
05/26 Oil Service Firms Investments Key To Halting Venezuela's Post-Maduro Producti..
05/26 Putting My Core Conviction Stocks To The Test
05/24 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2017 Upda..
05/24 What Do You Do When Social Security Falls Short Of Your Needs?
05/22 My 83 Stock Portfolio Requirements And Listing Of Do Not Sell, Core And Specu..
Advertisement
Financials ($)
Sales 2017 184 339 M
EBIT 2017 10 170 M
Net income 2017 5 384 M
Debt 2017 24 592 M
Yield 2017 2,56%
P/E ratio 2017 14,82
P/E ratio 2018 13,04
EV / Sales 2017 0,55x
EV / Sales 2018 0,53x
Capitalization 77 378 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 86,8 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-2.88%77 378
WALGREENS BOOTS ALLIAN..-1.82%87 287
EXPRESS SCRIPTS HOLDIN..-13.13%36 073
MCKESSON CORPORATION15.60%34 242
CARDINAL HEALTH INC2.04%23 198
AMERISOURCEBERGEN CORP..16.52%19 894
More Results